SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris Sells 30,000 Shares

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $53.13, for a total value of $1,593,900.00. Following the transaction, the chief operating officer now owns 189,712 shares of the company’s stock, valued at $10,079,398.56. This represents a 13.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Badreddin Edris also recently made the following trade(s):

• On Tuesday, December 3rd, Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $41.97, for a total value of $839,400.00.

SpringWorks Therapeutics Trading Down 1.2 %

SWTX opened at $58.59 on Friday. The company has a market capitalization of $4.36 billion, a price-to-earnings ratio of -15.10 and a beta of 0.81. SpringWorks Therapeutics, Inc. has a 12-month low of $28.21 and a 12-month high of $60.00. The business’s fifty day simple moving average is $38.69 and its 200-day simple moving average is $36.56.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.03. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The business had revenue of $49.10 million during the quarter, compared to analyst estimates of $53.28 million. During the same quarter in the previous year, the business posted ($1.27) EPS. The company’s quarterly revenue was up 4810.0% compared to the same quarter last year. On average, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -3.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Guggenheim reduced their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Wedbush restated an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a research report on Monday. Evercore ISI boosted their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $70.83.

Hedge Funds Weigh In On SpringWorks Therapeutics

A number of large investors have recently bought and sold shares of the business. Huntington National Bank boosted its position in SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after purchasing an additional 192 shares in the last quarter. AlphaQuest LLC grew its stake in SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after buying an additional 414 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in SpringWorks Therapeutics during the 4th quarter valued at about $45,000. KBC Group NV grew its stake in shares of SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company’s stock worth $95,000 after acquiring an additional 978 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock valued at $87,000 after acquiring an additional 474 shares in the last quarter.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.